FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Phase 1

Completed

Conditions: Recurrent Adult Hodgkin Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Childhood Non-Hodgkin Lymphoma
Refractory Childhood Hodgkin Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
T-Cell Chronic Lymphocytic Leukemia
T-Cell Prolymphocytic Leukemia
Recurrent Childhood Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cyclophosphamide
Drug: Cyclosporine
Drug: Cytarabine
Drug: Etoposide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Biological: Therapeutic Autologous Lymphocytes
Radiation: Total-Body Irradiation

First Posted Date: 2003-01-27

Last Posted Date: 2020-01-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 76

Registration Number: NCT00005803

Locations: 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸
LDS Hospital, Salt Lake City, Utah, United States
🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States

and more 2 locations

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2017-05-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00049504

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

Phase 2

Conditions: Graft-vs-Host Disease

First Posted Date: 2002-03-18

Last Posted Date: 2005-06-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 80

Registration Number: NCT00032279

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 14 locations

Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis

Phase 2

Completed

Conditions: Systemic Sclerosis

First Posted Date: 2001-05-07

Last Posted Date: 2008-09-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00016458

Locations: 🇺🇸
University of Colorado Cancer Center, Denver, Colorado, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis

Phase 1

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2001-04-11

Last Posted Date: 2005-06-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 35

Registration Number: NCT00014755

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
University of Colorado Cancer Center, Denver, Colorado, United States

and more 3 locations

Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders

Phase 1

Completed

Conditions: Autoimmune Diseases
Systemic Sclerosis
Dermatomyositis
Systemic Lupus Erythematosus
Juvenile Rheumatoid Arthritis

Interventions: Procedure: Stem Cell Transplantation
Device: CD34 selection

First Posted Date: 2001-02-02

Last Posted Date: 2015-03-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00010335

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders

Not Applicable

Completed

Conditions: Metabolism, Inborn Errors
Granulomatous Disease, Chronic

First Posted Date: 2001-02-02

Last Posted Date: 2014-12-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00010361

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant

Phase 1

Completed

Conditions: Adenosine Deaminase Deficiency
Autosomal Recessive Disorder
Immune System Disorder
Purine-Nucleoside Phosphorylase Deficiency
Severe Combined Immunodeficiency
Severe Combined Immunodeficiency With Absence of T and B Cells
X-Linked Severe Combined Immunodeficiency

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Drug: Cyclosporine
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Radiation: Total-Body Irradiation

First Posted Date: 2001-01-08

Last Posted Date: 2019-07-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00008450

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Bone Marrow Transplantation in Treating Children With Sickle Cell Disease

Phase 1

Completed

Conditions: Sickle Cell Anemia

First Posted Date: 1999-10-19

Last Posted Date: 2008-09-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00004485

Locations: 🇺🇸
Children's Hospital of Oakland, Oakland, California, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy